Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!

About | View Sample | Privacy

Hottest Products

Compare Top Solutions in:

Evaluate more than 400,000 products >>

Events

ExL Pharma's Digital Marketing for Medical Devices: West
April 30- May 2, 2012 — Hilton San Diego Resort & Spa, San Diego, CA
CBI's 11th Patient Adherence
April 26-27 — Philadelphia, PA
CBI's 3rd eTMF Boot Camp
May 15-16 — Philadelphia, PA
USP Pharmacopieal Education Spring Series
April 3-5 — Rockville, MD

More Events >>

Related Tags >> Vaccine Pfizer Prevnar-13 Boostrix

FDA approval News

Most Popular FDA approval Story

AstraZeneca's FluMist Quadrivalent to hit U.S. market

March 1, 2012 — 5:03am ET | By Suzanne Elvidge

The FDA has approved AstraZeneca's ($AZN) nasal FluMist Quadrivalent flu vaccine for use in people ages 2 to 49. Made at AstraZeneca's MedImmune unit, FluMist Quadrivalent contains two Read more...

FDA approval Press Releases

Mylan Receives Tentative FDA Approval for Generic Version of Lipitor®
Fibrocell Science, Inc. Announces Recognition for LAVIV™ (azficel-T) at The 2012 Cell & Gene Therapy Forum, Washington, D.
Genzyme Announces FDA Approval of Framingham Manufacturing Plant
Anika Therapeutics Announces U.S. MONOVISC® License and Supply Agreement with DePuy Mitek, Inc.
AIBioTech LLC Assists EUSA Pharma in Obtaining FDA approval for a Critical Drug Product

Latest Headlines

AstraZeneca's FluMist Quadrivalent to hit U.S. market
March 1, 2012
FDA approves Pfizer's Prevnar 13 for adults over 50
January 4, 2012
Prevnar 13: Pfizer's next Lipitor?
February 24, 2010
Novartis wins OK for new Japanese Encephalitis jab
April 1, 2009
FDA approves sBLA for BioThrax
December 23, 2008
Expanded indication for GSK's Boostrix approved
December 10, 2008

Paid Research Reports

Trends in mHealth and Telemedicine
The Global Aesthetic Dermatology Market Outlook
Future Directions in Regenerative Medicine
Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

More Research Reports >>

THE FIERCEMARKETS NETWORK